PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.47%
R&D growth exceeding 1.5x Biotechnology median of 5.15%. Jim Chanos would check for wasteful spending.
-1.59%
G&A reduction while Biotechnology median is 0.24%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.64%
Operating expenses growth 1.25-1.5x Biotechnology median of 11.19%. Guy Spier would scrutinize spending.
14.64%
Total costs growth 1.25-1.5x Biotechnology median of 10.84%. Guy Spier would scrutinize spending.
No Data
No Data available this quarter, please select a different quarter.
8.11%
D&A growth exceeding 1.5x Biotechnology median of 0.13%. Jim Chanos would check for overinvestment.
-14.78%
EBITDA decline while Biotechnology median is -6.28%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Operating income decline while Biotechnology median is -7.64%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-24.66%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-15.16%
Pre-tax income decline while Biotechnology median is -4.69%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
14.88%
Tax expense change of 14.88% versus flat Biotechnology. Walter Schloss would verify strategy.
-15.16%
Net income decline while Biotechnology median is -4.62%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
2.78%
EPS change of 2.78% versus flat Biotechnology. Walter Schloss would verify quality.
2.78%
Diluted EPS change of 2.78% versus flat Biotechnology. Walter Schloss would verify quality.
19.07%
Share count reduction below 50% of Biotechnology median of 0.01%. Jim Chanos would check for issues.
19.07%
Diluted share change of 19.07% versus stable Biotechnology. Walter Schloss would verify approach.